After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

Johnson & Johnson has reported Phase III data where CARVYKTI improved overall survival in patients with multiple myeloma.

Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly ...

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...

Johnson & Johnson reported long-term Phase III CARTITUDE-4 study results showing that a single infusion of Carvykti ...

Legend Biotech said Friday its cancer drug, Carvykti, lowered the risk of death by 45% in a study of multiple myeloma patients.

Johnson & Johnson (NYSE:JNJ) and Legend Biotech (NASDAQ:LEGN) said a long-term study showed their cell therapy Carvykti ...

Legend Biotech's valuation is conservative, suggesting potential for significant appreciation and growth ahead. Click here to ...

Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced three-year follow-up data from the Phase 3 CARTITUDE-4 study ...

Carvykti (ciltacabtagene autoleucel) is a prescription drug used to treat certain types of multiple myeloma. Carvykti comes as a liquid suspension for intravenous (IV) infusion given just one time.

RIO DE JANEIRO - Johnson & Johnson (NYSE:JNJ (NYSE:JNJ)) revealed findings from the Phase 3 CARTITUDE-4 study, indicating that CARVYKTI (ciltacabtagene autoleucel) significantly improves overall ...